Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation

Cancer Investigation

Volumn 26, Issue 8, 2008, Pages 822-829

  Gu, Pingqing ^a   Su, Yajuan ^b   Guo, Shuyu ^b   Teng, Lichen ^b   Xu, Ye ^a   Qi, Juan ^a   Gong, Hui ^a   Cai, Youqun ^a  

^a WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Human ovarian cancer cell (CAOV 3); Migration; PI3 k Akt; Proliferation; Viability

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHROMONES; CYCLOOXYGENASE 2; DNA REPLICATION; FEMALE; HUMANS; MORPHOLINES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 53949086081     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801941860     Document Type: Article

References (25)

1. Lorusso, D.; Ferrandina, G.; Graggi, S.; Gadduci, A.; Pignata, S.; Tateo, S.; Bia-monte, R.; Manzione, L.; Di Vagno, G.; Ferrau, F.; Scambia, G. Phase III multicenter randomized trial of amifostine as cytoprotect-ant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14, 1086-1093.
2. Melichar, B.; Urbanek, L.; Krcmova, L.; Kalabova, H.; Svobodova, I.; Drag-ounova, E.; Vesely, P.; Hyspler, R.; Solichova, D. Urinary neopterin in patients with ovarian cancer. Pteridines 2006, 17, 145-153.
3. McGuire, W.P.; Hoskins, W.J.; Brady, MF.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cis-platin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334, 1-6.
4. Cok, S.J.; Acton, S.J.; Morrison, A.R. The proximal region of the 3-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J Biol Chem 2003, 278, 36157-36162.
5. Dixon, D.A. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 2004, 10, 635-646.
6. Dixon, D.A.; Balch, G.C.; Kedersha, N.; Anderson, P.; Zimmerman, G.A.; Beauchamp, R.D.; Prescott, S.M. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 2003, 198, 475-481.
7. Dixon, D.A.; Tolley, N.D.; King, P.H.; Nabors, L.B.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Investig 2001, 108, 1657-1665.
8. Mukhopadhyay, D.; Houchen, C.W.; Kennedy, S.; Dieckgraefe, B.K.; Anant, S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2 Mol Cell 2003, 11, 113-126.
9. Muller-Decker, K.; Neufang, G.; Berger, I.; Neumann, M.; Marks, F.; Furstenberger, G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002, 99, 12483-12488.
10. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
11. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96, 857-868.
12. Gao, L.J.; Qiu, W.; Wang, Y.W.; Xu, W.H.; Xu, J.; Tong, J.X. Sublytic Complement C5b-9 Complexes Induce Thrombospondin-1 Production in Rat Glomerular Mesangial cells via PI3-k/Akt: Association with Activation of latent Transforming Growth Factor-β1. Clin Exp Immu 2006, 144, 326-334.
13. Roymans, D.; Slegers, H. Phosphoinositide 3-kinase in tumor progression. Eur J Biochem 2001, 268, 487-498.
14. Shimamura, H.; Terada, Y.; Okado, T.; Tanaka, H.; Inoshita, S.; Sasaki, S. The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-κB and Bad. J Am Soc Nephrol 2003, 14, 1427-1434.
15. Simon, A.R.; Vikis, H.G.; Stewart, S.; Fanburg, B.L.; Cochran, B.H.; Regulation of Stat3 by direct binding to the Rac1 GTPase. Science, 2000, 290, 144-147.
16. Stofega, M.R.; Argetsinger, L.S.; Wang, H.; Ullrich, A.; Carter-Su, C. Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha. J Biol Chem 2000, 275, 28222-28229.
17. Jemal, A.; Murray, T.;Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer E.J.; Thun, M.J.; Cancer Statistics, 2005, CA Cancer J Clin 55(1), 10-30.
18. Kawamori, T.; Wakabayashi, K.; COX-2 and prostanoid receptors: good targets for chemoprevention. J Environ Pathol Toxicol Oncol 2002, 21(2), 149-153.
19. Hanif, R.; Pittas, A.; Feng, Y.; Koutsos, M.I.; Qiao, L.; Staiano-Coico, L.; Shiff, S.I.; Rigas, B.; Effects of nonsteroidal anti-inflamatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52, 237-245.
20. Yu, H.P.; Shi, L.Y.; Lu, W.H.; Su, Y.H.; Li, Y.Y.; Xu, S.Q. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004, 19, 638-642.
21. Choi, E.M.; Kwak, S.J.; Kim, Y.M.; Ha, K.S.; Kim, J.I.; Lee, S.W.; Han, J.A. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 2005, 37, 199-203.
22. Liu, X.H.; Yao, S.; Kirschenbaum, A.; Levine, A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res 1998, 58, 4245-4249.
23. Hida, T.; Leyton, J.; Makheja, A.N.; Ben-Av, P.; Hla, T.; Martinez, A.; Mulshine, J.; Malkani, S.; Chung, P.; Moody, T.W. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 1998, 18, 775-782.
24. Kim, S.H.; Song, S.H.; Kim, S.G.; Chun, K.S.; Lim, S.Y.; Na, H.K.; Kim, J.W.; Surh, Y.J.; Bang, Y.J.; Song, Y.S. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NFkappaB as a possible target. J Cancer Res Clin Oncol 2004, 130, 551-560.
25. Shimamura, H.; Terada, Y.; Okado, T.; Tanaka, H.; Inoshita, S.; Sasaki, S. The Pi3-Kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-κB and Bad. J Am Soc Nephrol 2003, 14, 1427-1434.